Loading stock data…
¥2,263-38.00 (-1.65%)
Astellas Pharma Inc.
Astellas Pharma Inc. in the Healthcare sector is trading at ¥2,262 with a market capitalization of $4.2T. Wall Street consensus targets ¥2,529 (14 analysts), implying a +11.8% move over the next 12 months. The stock is currently 17% below its 52-week high of ¥2,717, remaining 0.3% above its 200-day moving average. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (JPY) · Annual | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
| Total Revenue | ¥1.52T↓ | ¥1.60T↓ | ¥1.91T↓ | ¥2.14T |
| Gross Profit | ¥1.23T↓ | ¥1.31T↓ | ¥1.56T↓ | ¥1.73T |
| Operating Income | ¥131.56B↑ | ¥18.95B↓ | ¥40.25B↓ | ¥380.06B |
| Net Income | ¥98.71B↑ | ¥17.05B↓ | ¥50.75B↓ | ¥291.54B |
Astellas Pharma Inc. engages in the research, development, manufacture, sale, and supply of pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYL...